MedTrace Logo

Clinical Trials

NCT04340843 | ACTIVE_NOT_RECRUITING | PHASE2
19 participants

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-09-08
Completion:
2024-02-22
Conditions
  • Locally Advanced Unresectable Primary Central Chondrosarcoma
  • Metastatic Primary Central Chondrosarcoma
  • Unresectable Primary Central Chondrosarcoma
Interventions
  • DRUG
  • PROCEDURE
Results Available
NCT04216316 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
12 participants

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2021-04-14
Completion:
2024-03-31
Conditions
  • Lung Non-Small Cell Squamous Carcinoma
  • Stage IV Lung Cancer AJCC v8
Interventions
  • DRUG
  • PROCEDURE
  • BIOLOGICAL
Results Available
NCT04175912 | ACTIVE_NOT_RECRUITING | PHASE2
40 participants

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-03-16
Completion:
2023-11-27
Conditions
  • Metastatic Cholangiocarcinoma
  • Metastatic Hepatocellular Carcinoma
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage III Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IIIB Hepatocellular Carcinoma AJCC v8
  • Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IV Hepatocellular Carcinoma AJCC v8
  • Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
  • Stage IVA Hepatocellular Carcinoma AJCC v8
  • Stage IVB Hepatocellular Carcinoma AJCC v8
  • Unresectable Cholangiocarcinoma
  • Unresectable Hepatocellular Carcinoma
  • Unresectable Intrahepatic Cholangiocarcinoma
Interventions
  • DRUG
Results Available
NCT04144972 | RECRUITING | NA
12 participants

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-10-24
Completion:
2029-10-24
Conditions
  • Spinal Cord Injuries
  • Nerve Injury
  • Pain, Postoperative
  • Post Herpetic Neuralgia
  • Complex Regional Pain Syndromes
  • Post-Stroke Pain
  • Post Radiation Brain Injury
  • Post Radiation Plexopathy
  • Nerve Root Avulsion
Interventions
  • DEVICE
No Results Yet
NCT04090398 | ACTIVE_NOT_RECRUITING | PHASE2
70 participants

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-08-04
Completion:
2027-06-30
Conditions
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Negative Breast Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
  • RADIATION
No Results Yet
NCT04079712 | ACTIVE_NOT_RECRUITING | PHASE2
17 participants

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-08-06
Completion:
2025-01-10
Conditions
  • Metastatic Large Cell Neuroendocrine Carcinoma
  • Metastatic Neuroendocrine Carcinoma
  • Metastatic Neuroendocrine Neoplasm
  • Metastatic Small Cell Neuroendocrine Carcinoma
Interventions
  • BIOLOGICAL
  • DRUG
Results Available
NCT04071223 | ACTIVE_NOT_RECRUITING | PHASE2
134 participants

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-07-29
Completion:
2026-10-01
Conditions
  • Advanced Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Clear Cell Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Kidney Medullary Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
  • Papillary Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer AJCC v8
  • Unclassified Renal Cell Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • OTHER
  • RADIATION
No Results Yet
NCT04068194 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
103 participants

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-04-07
Completion:
2027-07-01
Conditions
  • Locally Advanced Malignant Solid Neoplasm
  • Locally Advanced Unresectable Cholangiocarcinoma
  • Locally Advanced Unresectable Gallbladder Carcinoma
  • Locally Advanced Unresectable Malignant Solid Neoplasm
  • Metastatic Cholangiocarcinoma
  • Metastatic Gallbladder Carcinoma
  • Metastatic Malignant Solid Neoplasm
  • Stage III Gallbladder Cancer AJCC v8
  • Stage IV Gallbladder Cancer AJCC v8
  • Unresectable Malignant Solid Neoplasm
Interventions
  • DRUG
  • PROCEDURE
  • RADIATION
No Results Yet
NCT04052555 | ACTIVE_NOT_RECRUITING | PHASE1
42 participants

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-09-24
Completion:
2027-02-24
Conditions
  • Bilateral Breast Carcinoma
  • HER2-Negative Breast Carcinoma
  • Localized Breast Carcinoma
  • Recurrent Breast Carcinoma
  • Triple-Negative Breast Carcinoma
Interventions
  • DRUG
  • PROCEDURE
  • OTHER
  • RADIATION
No Results Yet
NCT04034927 | ACTIVE_NOT_RECRUITING | PHASE2
61 participants

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-12-04
Completion:
2021-07-31
Conditions
  • Fallopian Tube Endometrioid Tumor
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Malignant Ovarian Endometrioid Tumor
  • Ovarian High Grade Serous Adenocarcinoma
  • Platinum-Sensitive Fallopian Tube Carcinoma
  • Platinum-Sensitive Ovarian Carcinoma
  • Platinum-Sensitive Primary Peritoneal Carcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT03914612 | ACTIVE_NOT_RECRUITING | PHASE3
813 participants

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-08-22
Completion:
2022-12-16
Conditions
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Dedifferentiated Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Recurrent Endometrial Adenocarcinoma
  • Recurrent Endometrial Carcinoma
  • Recurrent Endometrial Clear Cell Adenocarcinoma
  • Recurrent Endometrial Dedifferentiated Carcinoma
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Endometrial Mixed Cell Adenocarcinoma
  • Recurrent Endometrial Serous Adenocarcinoma
  • Recurrent Endometrial Undifferentiated Carcinoma
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
  • DRUG
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
Results Available
NCT03914300 | ACTIVE_NOT_RECRUITING | PHASE2
11 participants

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2020-02-10
Completion:
2024-10-17
Conditions
  • Differentiated Thyroid Gland Carcinoma
  • Follicular Variant Thyroid Gland Papillary Carcinoma
  • Poorly Differentiated Thyroid Gland Carcinoma
  • Refractory Differentiated Thyroid Gland Carcinoma
  • Refractory Thyroid Gland Carcinoma
  • Tall Cell Variant Thyroid Gland Papillary Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Oncocytic Carcinoma
  • Thyroid Gland Papillary Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
Results Available
NCT03896503 | ACTIVE_NOT_RECRUITING | PHASE2
104 participants

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-12-30
Completion:
2022-12-19
Conditions
  • Extensive Stage Lung Small Cell Carcinoma
  • Extrapulmonary Small Cell Neuroendocrine Carcinoma
  • Limited Stage Lung Small Cell Carcinoma
  • Platinum-Resistant Lung Small Cell Carcinoma
  • Platinum-Sensitive Lung Small Cell Carcinoma
  • Recurrent Lung Small Cell Carcinoma
Interventions
  • DRUG
  • PROCEDURE
Results Available
NCT03872427 | ACTIVE_NOT_RECRUITING | PHASE2
54 participants

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-12-14
Completion:
2023-10-30
Conditions
  • Advanced Malignant Solid Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
  • Unresectable Malignant Solid Neoplasm
Interventions
  • PROCEDURE
  • OTHER
  • DRUG
Results Available
NCT03816345 | RECRUITING | PHASE1
300 participants

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-07-16
Completion:
2028-03-30
Conditions
  • Autoimmune Disease
  • Crohn Disease
  • Dermatomyositis
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Inflammatory Bowel Disease
  • Malignant Solid Neoplasm
  • Multiple Sclerosis
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Sjogren Syndrome
  • Systemic Lupus Erythematosus
  • Systemic Scleroderma
  • Ulcerative Colitis
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT03816332 | ACTIVE_NOT_RECRUITING | PHASE1
12 participants

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-11-08
Completion:
2022-10-11
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
  • Metastatic Basal Cell Carcinoma
  • Metastatic Melanoma
  • Metastatic Merkel Cell Carcinoma
  • Metastatic Skin Squamous Cell Carcinoma
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8
  • Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
  • Pathologic Stage IIID Cutaneous Melanoma AJCC v8
  • Pathologic Stage IV Cutaneous Melanoma AJCC v8
  • Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
  • Unresectable Basal Cell Carcinoma
  • Unresectable Melanoma
  • Unresectable Merkel Cell Carcinoma
Interventions
  • BIOLOGICAL
  • DRUG
Results Available
NCT03796273 | TERMINATED | EARLY_PHASE1
15 participants

Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases

Study Type:
INTERVENTIONAL
Last Updated:
2026-07-31
Start Date:
2019-03-13
Completion:
2022-10-23
Conditions
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Astrocytoma
  • Breast Carcinoma Metastatic in the Brain
  • Glioma
  • Invasive Breast Carcinoma
  • Oligodendroglioma
  • Prognostic Stage IV Breast Cancer AJCC v8
  • Recurrent Glioma
Interventions
  • OTHER
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page